



# Atrial Fibrillation Screening in General Practice for Stroke Prevention

**Associate Professor Bryan Yan**

Head (Academic Affairs), Division of Cardiology

Department of Medicine & Therapeutics

The Chinese University of Hong Kong


# Learning Objectives



Why Screen?	Who to Screen?	How to Screen?	Role of GP in AF Screening?
AF leads to significant mortality & morbidity	Patients who at risk of developing AF & stroke	<ul style="list-style-type: none"><li>- Palpation</li><li>- Hand-hand ECG devices</li><li>- BP monitor</li></ul>	<ul style="list-style-type: none"><li>- Patient education</li><li>- Prescription of OAC</li><li>- Ensure OAC Adherence</li></ul>


# Why Screen for AF?

- Most common cardiac arrhythmia
- Growing prevalence with ageing population
  - Expected to double 3.9 to 9 million in China by 2050



# AF Related Stroke

- **5x** increased risk of stroke
  - Up to 30% of ischemic stroke AF related
- AF-related stroke more severe
  - 20% death
  - 60% disability
- Healthcare burden could be reduced if AF related stroke can be prevented



# Diagnostic Challenge



## Identify AF before stroke occurs

- AF 1<sup>st</sup> diagnosed at time of stroke (~20%)
- AF often asymptomatic & many unaware they have AF
- Screening is necessary to identify asymptomatic AF
- Early AF detection provide opportunity to prevent strokes by initiating appropriate oral anticoagulation therapy

# Treatment Challenges



## Therapeutic & Knowledge gaps in Hong Kong

- Up to 50% known AF sub-optimally treated<sup>1</sup>
- Poor patient awareness of AF<sup>2</sup>
- Poor long-term compliance with oral anticoagulation therapy<sup>3</sup>
- Suboptimal physician knowledge & adherence to guidelines<sup>4</sup>

1. Yan BP. Unpublished data

2. Lee VWY, Yan BP, et al. Clinical Cardiology . 2013

3. Wang ZZ et al. Circ Cardiovasc Qual Outcomes. 2016



4. Lee VWY, Yan BP, et al. Clinical Cardiology . 2012

# Incidentally Detected AF is Not Benign



Incidental AF (Holter monitor) = 5,555  
Matched Control = 24,705


- Mean age = 70.9
- Mean CHA2DS2VASc Score = 2.1



# Asymptomatic & Symptomatic AF have Similar Risk of Stroke



- ORBIT AF Registry





# Rationale for AF Screening



WHO Criteria for Screening *	Applicability of AF Screening
Condition should be an important health problem	<b>YES</b> , AF is common with rising prevalence & major cause for stroke & associated with increased mortality, morbidity & reduced QOL
Natural history of the condition should be adequately understood	<b>YES</b> , it is generally agreed that AF causes stroke & there is clear mechanism for treatment
Detectable early stage	<b>YES</b> , AF is readily detectable with simple measures
Accepted treatment at an early stage should be more benefit than later stage	<b>YES</b> , all guidelines agree OAC should be given to patients at high risk of stroke unless bleeding risk is very high
Suitable test for early stage	<b>YES</b> , a number of tests are suitable both pulse-based & ECG-based with single- or multi-time point testing
Test should be acceptable	<b>YES</b> , pulse check, ECG & smart-devices are simple & non-invasive
Interval for repeating the test should be known	<b>YES &amp; NO</b> , permanent AF is easily detected with a single ECG recording but no consensus for paroxysmal AF
Adequate health service provision for extra workload resulting from screening	<b>YES</b> , AF screening is likely to be cost effective & potentially life-saving. Additional clinical workload is minimal in most cases
Risk of screening (physical & psychological) should be less than benefits	<b>YES</b> , negligible physical risk & most patients find process reassuring and grateful for early detection
Cost of case (including diagnosis & treatment) should be economically viable	<b>YES</b> , recent studies showed AF screening is likely to be cost effective

\*Wilson & Jungner. Principle of Screening for Disease. WHO. 1968

# Screening Strategies for AF: Systematic Review & Cost-effectiveness Analysis



Welton NJ, et al. HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 29

**Conclusions:** A national screening programme for AF is likely to represent a cost-effective use of resources. Systematic opportunistic screening is more likely to be cost-effective than systematic population screening. Nurse pulse palpation or modified blood pressure monitors would be appropriate screening tests, with confirmation by diagnostic 12-lead electrocardiography interpreted by a trained GP, with referral to a specialist in the case of an unclear diagnosis. Implementation strategies to operationalise uptake of systematic opportunistic screening in primary care should accompany any screening recommendations.

## Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland

Patrick S. Moran, PhD<sup>1,2,\*</sup>, Conor Teljeur, PhD<sup>2,3</sup>, Patricia Harrington, PhD<sup>2</sup>, Susan M. Smith, MD<sup>4</sup>, Breda Smyth, MD<sup>5</sup>, Joseph Harbison, MD<sup>6</sup>, Charles Normand, DPhil<sup>7</sup>, Máirín Ryan, PhD<sup>2,8</sup>

## Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies

The SEARCH-AF study

Australia

European Society of Cardiology doi:10.1093/europace/euw285

CLINICAL RESEARCH  
Atrial fibrillation

Canadian Journal of Cardiology 34 (2018) 1522–1525

Training/Practice  
Health Policy and Promotion

## Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?

## Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands

# Who to Screen?

## Risk factors for AF (Framingham Cohort)

- Male
- **Age >65**
- **Diabetes**
- **Hypertension**
- **CAD/heart failure**
- Smoking
- Obesity
- Sleep Apnoea
- COPD
- Positive family history of AF
- **History of stroke & thyroid disease**

## CHA<sub>2</sub>DS<sub>2</sub>VASc Score

Risk Factor
<b>C</b> - Congestive heart failure
<b>H</b> - Hypertension
<b>A</b> - Age ≥ 75 yrs
<b>D</b> - Diabetes mellitus
<b>S<sub>2</sub></b> - Prior stroke or TIA
<b>V</b> - Vascular disease
<b>A</b> - Age 65-74 years old
<b>Sc</b> - Sex category (female)

# Latest ESC Guidelines (2016)


Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref <sup>c</sup>
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients >65 years of age.	<b>I</b>	<b>B</b>	130, 134, 155
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous ECG monitoring for at least 72 hours.	<b>I</b>	<b>B</b>	27, 127
It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE should undergo further ECG monitoring to document AF before initiating AF therapy.	<b>I</b>	<b>B</b>	141, 156
In stroke patients, additional ECG monitoring by long-term non-invasive ECG monitors or implanted loop recorders should be considered to document silent atrial fibrillation.	<b>IIa</b>	<b>B</b>	18, 128
Systematic ECG screening may be considered to detect AF in patients aged >75 years, or those at high stroke risk.	<b>IIb</b>	<b>B</b>	130, 135, 157

# How to Screen?

## CLINICAL SCREENING



RISK SCORES



PULSE TAKING




AUTOMATED BLOOD PRESSURE MONITORS

## > NEW TOOLS



PHOTOPLETHYSMOGRAPHIC APP




SMARTPHONE + CASING ELECTRODE




SMARTPHONE HANDHELD ECG


## ECG SCREENING > SINGLE LEAD




ELECTRODE STICK



SINGLE-CHANNEL ECG MONITOR




MONITORING PATCH




WATCH-LIKE RECORDER


## IMPLANTED DEVICES



PACEMAKER



IMPLANTABLE CARDIOVERTER DEFIBRILLATOR



IMPLANTABLE LOOP RECORDER



TELEMETRY

# Pulse Palpation



- Traditional, simple & should be routine practice
- Pulse is infrequently assessed in 'real world' practice
  - Expert recommend 1 minutes palpation<sup>2</sup>
  - Automatic BP & pulse rate machines
- Diagnostic accuracy depends on training & expertise<sup>1</sup>
  - Sensitivity = 0.94 (0.87-0.97)
  - Specificity = **0.72** (0.69-0.75)
- Confirmatory ECG takes time, space & staff
  - 1 in 10 ECG may require further investigations for abnormalities
  - Many primary care physicians cannot accurately detect AF on ECG<sup>3</sup>



1. Taggar JS, et al. Eur J Prev Cardiol, 2016; 23(12)
2. Sneed N, et al. J Crit Care. 1991; 21(5)
3. Martin J, et al. BMJ 335(7616):380

# AliveCor™ Heart Monitor



- Real-time high-grade single-lead ECG tracing
  - Smartphone, tablet, Apple Watch
- Automatic AF detection algorithm
  - 30 seconds recording
  - Presence of P wave & RR irregularity
  - High sensitivity (98%) & specificity (97%)<sup>1</sup>
- US FDA approved
  - Advise ECG reading is “normal” or “possible AF”



Kardia Band



Kardia Mobile ECG (4th Generation)  
AC-009-UA-C



# Contact-Free Facial AF Detection


- Pulsatile PPG signals from beat-to-beat variations of facial skin color reflects cardiac pulsatile signal similar to heart beat




	Facial PPG	Fingertip PPG
No. of subjects	217	
Sensitivity	<b>94.7%</b>	94.7%
Specificity	<b>95.8%</b>	93.0%
Accuracy	<b>95.4%</b>	93.5%

- Convenience of contact free approach attractive for community screening & potential for distal AF screening

## (A) Sinus rhythm




## (B) Atrial fibrillation





# Proof-of-concept Study: Simultaneous Multi-facial AF Detection



- Digital SLR
- Automatic facial recognition & identify “region-of-interest”
- 5 facial PPG signals extracted from video
- Pulse irregularity in >50% considered AF

Inter-method Reliability		ECG		
		(32 combinations recorded 2 times)		
		AF	SR	Total
PPG (32 combinations recorded 2 times)	AF	154	7	161
	SR	6	153	159
	<b>Total</b>	160	160	320
<b>Cohen's K coefficient</b>		<b>0.92 (CI 0.88-0.96)</b>		
Range across 32 combinations		0.55-1.00		
Range across 5 seating positions		0.84-1.00		
<b>Agreement</b>		<b>95.9%</b>		
Range across 32 combinations		80.0-100.0%		
Range across 5 seating positions		92.2-96.9%		

# Circulation

STATE OF THE ART

## Screening for Atrial Fibrillation

A Report of the AF-SCREEN International Collaboration



Ben Freedman, John Camm, Hugh Calkins, Jeffrey S. Healey, Mårten Rosenqvist, Jiguang Wang, Christine M. Albert, Craig S. Anderson, Sotiris Antoniou, Emelia J. Benjamin, Giuseppe Boriani, Johannes Brachmann, Axel Brandes, Tze-Fan Chao, David Conen, Johan Engdahl, Laurent Fauchier, David A. Fitzmaurice, Leif Friberg, Bernard J. Gersh, David J. Gladstone, Taya V. Glotzer, Kylie Gwynne, Graeme J. Hankey, Joseph Harbison, Graham S. Hillis, Mellanie T. Hills, Hooman Kamel, Paulus Kirchhof, Peter R. Kowey, Derk Krieger, Vivian W. Y. Lee, Lars-Åke Levin, Gregory Y. H. Lip, Trudie Lobban, Nicole Lowres, Georges H. Mairesse, Carlos Martinez, Lis Neubeck, Jessica Orchard, Jonathan P. Piccini, Katrina Poppe, Tatjana S. Potpara, Helmut Puererfellner, Michiel Rienstra, Roopinder K. Sandhu, Renate B. Schnabel, Chung-Wah Siu, Steven Steinhubl, Jesper H. Svendsen, Emma Svennberg, Sakis Themistoclakis, Robert G. Tieleman, Mintu P. Turakhia, Arnljot Tveit, Steven B. Uittenbogaart, Isabelle C. Van Gelder, Atul Verma, Rolf Wachter, **Bryan P. Yan**

DOI <https://doi.org/10.1161/CIRCULATIONAHA.116.026693>

Circulation. 2017;135:1851-1867

**1 of 5 Key Messages:**  
Setting for AF screening should be both  
country- & health system-specific.

AF-SCREEN is an international collaboration of >100 health care professionals from **31** countries formed in 2015 (including cardiologists, electrophysiologists, neurologists, geriatricians, epidemiologists, health economists, primary care physicians, nurses, pharmacists, physiotherapists & patient advocates)

# More Screening Increases AF Yield



Study	Method	Device	Target	New AF Detected	NNS
<i>Lowres N, et al. Thromb Haemost 2103</i>	Single-time point	Handheld ECG	>65	<b>1.4%</b>	71
<b>STROKESTOP</b> <i>Svennberg E, et al. Circulation 2015</i>	2 week twice daily	Handheld ECG	75-76	<b>3.0%</b>	33
<b>REHEARSE-AF</b> <i>Halcox JP, et al. Circulation 2017</i>	12 months twice weekly	Handheld ECG	>75 (younger with risk factors)	<b>3.8%</b>	26
<b>mSToPS</b> <i>Steinhubl S, et al. JAMA 2018</i>	2 weeks continuous	ECG patch	>65 with risk factors	<b>3.9%</b>	26

# Community AF Screening in Hong Kong



Study	Population	Mean Age	Device	New AF Detected
<i>Chan NY, et al. Heart. 2017</i>	13,122 General pop	64.7±13.4	Hand-held ECG	<b>0.8%</b>
<i>Yan BP, et al. ISPOR 2016, Washington</i>	2,767 (26 elderly centres)	80.3±7.1	Hand-held ECG	<b>5.1%</b>

# Out-patient Clinic AF Screening in Hong Kong



Study	Population	Strategy	Mean Age	Device	New AF
<i>Chan PH, et al. BMJ Open. 2017</i>	5,969 GOPC	Single-time point	67±11	BP monitor	<b>1.21%</b>
<i>Yan BP, et al. ESC 2017, Barcelona</i>	11,972 7 Medical SOPC @PWH	40% repeated screening at 6-12 months interval	76±8	Hand-held ECG	<b>3.0% Overall</b> <b>2.3% 1<sup>st</sup> Time</b>

# AF Screening in General Practice: Pilot Study



- 1041 patients  $\geq 65$  years old (9 GP Clinics)
  - AliveCor hand-held ECG

**Table 3. Evaluation of the impact of AF screening from GPs (n=7).**

Do you find the ECG device useful for AF screening?		
No/Rarely	0	
Sometimes	14% (1)	
Yes	86% (6)	
How often do you use CHA <sub>2</sub> DS <sub>2</sub> -VASc score for AF patients?		
	Before AF screening	After AF screening
Never/Rarely	43% (3)	29% (2)
Sometimes	14% (1)	0
Often/Always	43% (3)	71% (5)

Do you agree the handheld ECG was easy to operate?		
Yes	100.0% (7)	75.0% (3)
Don't know	0	25.0% (1)
Are you willing to be screened for AF again in the future?		
Yes	100.0% (7)	100.0% (4)
Don't know	0	0

# Role of GP in AF Screening



Primary prevention

Screening/  
diagnosis

Diagnosis/management/  
risk stratification



Sinus rhythm

Sub-clinical AF

Clinical AF


Complications

- AF screening & diagnosis
- Assess stroke risk & bleeding
- Initiate OAC if indicated
- Lifestyle interventions
- Patient education & empowerment


# Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry

15,092 (Asia 3,071) new AF (>50 countries)

A Antithrombotic treatment by region (entire population)




Asia





# *Opportunity to improve stroke prevention in known AF patients identified during screening*



**Known AF  
n=1,935**

■ No treatment   ■ Not adequate treatment   ■ Warfarin   ■ NOAC   ■ LAAO

# Opportunity to improve patient knowledge gaps



Table 3: Respondents' pre-screening knowledge of facts about atrial fibrillation

## EVALUATION: Internal Medicine AF Screening


	Yes, I knew	N	No, I did not know	N	Total
Women with AF have a higher risk of stroke than men.	33.10%	188	66.90%	380	568
AF strokes are much more dangerous than other types of strokes.	21.14%	119	78.86%	444	563
The risk of stroke is much higher if you have AF that is not treated.	54.23%	308	45.77%	260	568
People living with AF are at risk for stroke even if they have irregular heartbeats only once in a while.	42.53%	242	57.47%	327	569
Most AF strokes are caused by a blood clot in the brain.	36.33%	206	63.67%	361	567
Physicians think about AF stroke risk when suggesting choices about treatment.	38.38%	218	61.62%	350	568
Blood thinners can greatly reduce the risk of AF stroke.	59.36%	336	40.64%	230	566
Even those with occasional AF are at risk for AF stroke.	42.50%	241	57.50%	326	567
Some AF patients may not have any noticeable symptoms.	46.02%	260	53.98%	305	565

Screening programs should take advantage of the opportunity to provide education regarding AF & stroke prevention, thereby increasing benefits to all participants

# Take Home Message:

## *Are We Ready for AF Screening?*

- AF is a growing problem & increases risk of stroke but is often diagnosed too late after stroke occurs
- Active, opportunistic screening (e.g. GP visit) in patients at risk of AF (aged >65) increases detection rates of asymptomatic AF
- Improved AF detection (by pulse palpation or handheld devices) will amount to little if adequate treatment strategies are not implemented
- GP can play key roles in AF screening & diagnosis of, stroke risk assessment, initiate OAC when appropriate & patient education to translate potential benefits of increased detection into improved stroke prevention, with the associated societal cost benefits & reduction in direct human costs of AF-related stroke



- AF-SCREEN preferred
- Possible with further data
- Currently too expensive at scale



Freedman B, Yan BP, et al. *Circulation*. 2017

# Thank You